Five-Year Outcomes from Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson Disease.

ABSTRACT:

Importance

The Implantable Neurostimulator for the Treatment of Parkinson's Disease (INTREPID) trial was a randomized, double-blind, sham-controlled study of subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of Parkinson disease (PD).

Objective

To evaluate the long-term (5-year) outcomes and safety of STN-DBS for PD.

Design, setting, and participants

This was a prospective, randomized (3:1), 12-week double-blind sham-controlled study at 23 movement disorder centers across the US with an open-label 5-year follow-up. Patients were implanted and followed up with the Vercise DBS system from May 2013 to December 2022. Eligibility required diagnosis of bilateral idiopathic PD with more than 5 years of motor symptoms, more than 6 hours per day of poor

SUBMITTER: Starr PA 

PROVIDER: S-EPMC12439180 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature